RPS9 Antibody

What is RPS9 and why is it significant in cellular biology?

RPS9 (Ribosomal Protein S9) is an essential component of the small 40S ribosomal subunit involved in protein synthesis. It functions as part of the small subunit (SSU) processome, the first precursor of the small eukaryotic ribosomal subunit. During ribosome biogenesis, RPS9 participates in RNA folding, modifications, rearrangements, and cleavage in the nucleolus, working with other factors to generate pre-ribosomal RNA . As a critical player in the translation machinery, dysregulation of RPS9 has been implicated in various diseases, including cancer and genetic disorders, making it an important target for molecular biology and genetics research .

What are the standard molecular characteristics of commercially available RPS9 antibodies?

Commercial RPS9 antibodies are predominantly rabbit polyclonal antibodies that specifically recognize the RPS9 protein. The calculated molecular weight of RPS9 is approximately 22-23 kDa, though observed molecular weights may vary (with one source reporting as high as 111 kDa in certain conditions) . Most RPS9 antibodies are supplied in liquid form in PBS containing preservatives such as glycerol (typically 50%) and sodium azide (0.02%), with BSA (0.5%) as a stabilizer . These antibodies are designed to detect endogenous levels of total RPS9 protein in various applications including Western blot, immunohistochemistry, immunofluorescence, and ELISA .

How should Western blot protocols be optimized for RPS9 detection?

For optimal Western blot results with RPS9 antibodies, researchers should consider the following protocol adjustments:

• Sample preparation: Extract proteins using a lysis buffer containing protease inhibitors to prevent degradation. For ribosomal proteins, consider using specialized ribosome extraction buffers.

• Gel selection: Use 10-15% SDS-PAGE gels for optimal separation of the ~23 kDa RPS9 protein.

• Transfer conditions: Use standard transfer protocols, but consider optimizing transfer time for small proteins (typically 60-90 minutes at 100V).

• Blocking: Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody: Dilute RPS9 antibody between 1:500 and 1:3000 in blocking buffer and incubate overnight at 4°C. The specific recommended dilutions vary by manufacturer: 1:500-1:2000 , 1:500-1:1000 , or 1:500-1:3000 .

• Secondary antibody: Use an appropriate HRP-conjugated anti-rabbit secondary antibody at a dilution of 1:5000-1:10000.

• Detection: Visualize using ECL substrate and adjust exposure time based on signal intensity.

Include appropriate positive controls such as HeLa cell lysates or tissue extracts from liver, brain, or spleen, which are known to express detectable levels of RPS9 .

What are the recommended protocols for immunohistochemistry with RPS9 antibodies?

For optimal immunohistochemistry results with RPS9 antibodies:

• Tissue preparation: Fix tissues in 10% neutral buffered formalin and embed in paraffin, or prepare frozen sections.

• Antigen retrieval: Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 8.0).

• Blocking: Block endogenous peroxidase activity with 3% H₂O₂ and prevent non-specific binding with 5-10% normal serum from the same species as the secondary antibody.

• Primary antibody: Apply RPS9 antibody at a dilution of 1:100 to 1:300 and incubate overnight at 4°C .

• Detection system: Use an appropriate detection system (HRP-polymer or ABC kit) and develop with DAB substrate.

• Counterstain: Counterstain with hematoxylin, dehydrate, clear, and mount.

When analyzing results, expect RPS9 to be predominantly cytoplasmic with some nucleolar localization, consistent with its role in ribosome assembly and function .

How can immunofluorescence protocols be optimized for RPS9 localization studies?

For successful immunofluorescence studies using RPS9 antibodies:

• Cell preparation: Culture cells on coverslips to 70-80% confluence.

• Fixation: Fix cells with 4% paraformaldehyde for 15 minutes at room temperature.

• Permeabilization: Permeabilize with 0.1-0.5% Triton X-100 for 5-10 minutes.

• Blocking: Block with 5% normal serum or BSA for 1 hour at room temperature.

• Primary antibody: Incubate with RPS9 antibody at 1:100-1:500 dilution overnight at 4°C .

• Secondary antibody: Apply fluorophore-conjugated anti-rabbit secondary antibody (1:500-1:1000).

• Nuclear counterstain: Counterstain nuclei with DAPI or Hoechst.

• Mounting: Mount with anti-fade mounting medium.

For co-localization studies, consider double staining with markers for nucleoli (nucleolin, fibrillarin) or cytoplasmic ribosomes (other ribosomal proteins) to better understand RPS9 distribution in different cellular compartments .

Why do observed molecular weights of RPS9 often differ from calculated predictions in Western blots?

The discrepancy between the calculated molecular weight of RPS9 (approximately 22-23 kDa) and observed molecular weights (which can be as high as 111 kDa) can be attributed to several factors :

• Post-translational modifications: RPS9 undergoes several modifications including phosphorylation (at T12, Y13, T15), methylation (at R5, K11), and ubiquitination (at K11), which can alter electrophoretic mobility .

• Protein complexes: Incomplete denaturation may result in detection of RPS9 within larger ribonucleoprotein complexes.

• SDS-resistant structures: Some ribosomal proteins can form SDS-resistant structures that migrate anomalously.

• Sample preparation conditions: Differences in sample buffer composition, heating time, and reducing agent concentration can affect observed molecular weights.

To address these inconsistencies, researchers should:

• Ensure complete denaturation by increasing SDS concentration and heating time

• Include strong reducing agents such as DTT or β-mercaptoethanol

• Run appropriate molecular weight markers and validate with known positive controls

• Consider using gradient gels for better resolution across a wide molecular weight range

What strategies can be employed to validate RPS9 antibody specificity?

To confirm antibody specificity for RPS9:

• Positive controls: Use cell lines known to express RPS9, such as HeLa, U2OS, or Jurkat cells .

• Negative controls: Perform the experiment without primary antibody or use samples where RPS9 expression is knocked down via siRNA/shRNA.

• Blocking peptide competition: Pre-incubate the antibody with the immunizing peptide before application. If staining is specific, the peptide should abolish or significantly reduce the signal.

• Orthogonal detection methods: Confirm results using multiple techniques (WB, IHC, IF) or multiple antibodies targeting different regions of RPS9.

• Genetic validation: Compare antibody signals in wild-type versus RPS9-depleted samples.

The discrepancy between the calculated molecular weight (22-23 kDa) and observed weight (sometimes 111 kDa) should be considered when evaluating specificity .

How should researchers address high background or non-specific staining with RPS9 antibodies?

To reduce high background and non-specific staining:

• Antibody dilution optimization: Test a range of dilutions; recommended ranges include 1:500-1:2000 for WB, 1:100-1:300 for IHC, and 1:200-1:1000 for IF .

• Blocking optimization: Increase blocking time or try alternative blocking agents (BSA, normal serum, commercial blocking reagents).

• Washing stringency: Increase the number, duration, and volume of washes between antibody incubations.

• Buffer optimization: Add detergents (0.1-0.3% Tween-20) or increasing salt concentration in wash buffers to reduce non-specific interactions.

• Antibody pre-adsorption: Pre-adsorb antibodies with tissue powder from the same species as the sample to remove cross-reactive antibodies.

• Secondary antibody considerations: Ensure the secondary antibody is appropriate for the host species of the primary antibody and has minimal cross-reactivity with the sample species.

For applications showing persistent high background, consider testing alternative RPS9 antibodies raised against different epitopes or from different manufacturers .

How can RPS9 antibodies be utilized to investigate ribosome biogenesis defects?

RPS9 antibodies provide valuable tools for studying ribosome biogenesis abnormalities:

• Nucleolar stress detection: Changes in RPS9 nucleolar/cytoplasmic distribution can indicate nucleolar stress response. Use immunofluorescence with RPS9 antibodies to monitor these changes under various stress conditions.

• Pre-ribosomal particle analysis: Immunoprecipitate pre-ribosomal particles using RPS9 antibodies to investigate assembly intermediates and their composition.

• Polysome profiling: Combine with sucrose gradient fractionation to analyze incorporation of RPS9 into different ribosomal complexes and detect assembly defects.

• Pulse-chase experiments: Track newly synthesized RPS9 incorporation into ribosomes using metabolic labeling followed by immunoprecipitation with RPS9 antibodies.

• Co-immunoprecipitation: Use RPS9 antibodies to identify novel interacting partners involved in ribosome assembly and maturation.

• Chromatin immunoprecipitation: Investigate potential roles of RPS9 in regulating ribosomal RNA transcription or processing.

These approaches help elucidate RPS9's role in the small subunit (SSU) processome and identify defects in ribosome biogenesis pathways that may contribute to disease .

What approaches can researchers use to study RPS9 post-translational modifications?

To investigate post-translational modifications (PTMs) of RPS9:

• PTM-specific antibodies: Use antibodies specifically targeting phosphorylated, methylated, or ubiquitinated forms of RPS9. Although not mentioned in the search results, these can be custom-developed for specific modified residues.

• Immunoprecipitation-mass spectrometry: Immunoprecipitate RPS9 using available antibodies followed by mass spectrometry to identify modifications at specific residues.

• 2D gel electrophoresis: Separate different post-translationally modified forms of RPS9 based on charge and molecular weight differences.

• Pharmacological interventions: Use kinase inhibitors, methyltransferase inhibitors, or proteasome inhibitors to study the dynamics of specific modifications.

• Mutagenesis studies: Generate point mutations at known PTM sites (T12, Y13, T15 for phosphorylation; R5, K11 for methylation; K11 for ubiquitination) and combine with RPS9 antibody detection to study functional consequences .

• Temporal analysis: Use RPS9 antibodies to track changes in modification patterns during cell cycle progression or stress responses.

These approaches can reveal how PTMs regulate RPS9 function in ribosome assembly, translation, and potentially extra-ribosomal functions.

How can RPS9 antibodies contribute to understanding the role of specialized ribosomes in disease states?

RPS9 antibodies can advance our understanding of specialized ribosomes in disease:

• Tissue-specific expression analysis: Use immunohistochemistry with RPS9 antibodies to compare expression levels and patterns across normal and diseased tissues.

• Cancer biomarker research: Evaluate RPS9 as a potential diagnostic or prognostic marker in cancer tissues using tissue microarrays and RPS9 antibodies.

• Ribosomopathy investigations: Study how mutations in ribosomal proteins affect RPS9 incorporation and function in congenital disorders.

• Selective mRNA translation studies: Combine polysome profiling with RPS9 immunoprecipitation to identify mRNAs preferentially translated by RPS9-containing ribosomes in normal versus disease states.

• Therapeutic target validation: Use RPS9 antibodies to evaluate the effects of potential therapeutics on ribosome composition and function.

• Extracellular vesicle characterization: Detect RPS9 in extracellular vesicles as potential biomarkers or intercellular signaling components.

By applying these approaches, researchers can determine whether alterations in RPS9 contribute to pathogenesis and whether targeting RPS9 or its interactions might offer therapeutic benefits .

What criteria should guide selection between different commercially available RPS9 antibodies?

When selecting an RPS9 antibody, researchers should consider these criteria:

Based on the search results, researchers can choose between antibodies with different immunogens: synthetic peptides derived from human RPS9 , recombinant fusion protein containing amino acids 1-162 , or peptides targeting specific regions like amino acids 31-80 . Each offers different advantages depending on the experimental context.

How do RPS9 antibody requirements differ across various experimental techniques?

Antibody requirements vary significantly across techniques:

• Western Blot:

  • Dilution: 1:500-1:3000 depending on the specific antibody

  • Key consideration: Ability to recognize denatured epitopes

  • Validation metric: Clean band at expected molecular weight (though variations occur)

• Immunohistochemistry:

  • Dilution: 1:100-1:300

  • Key consideration: Compatibility with fixation methods and antigen retrieval

  • Validation metric: Specific cellular localization pattern with minimal background

• Immunofluorescence:

  • Dilution: 1:100-1:1000

  • Key consideration: Signal-to-noise ratio and co-localization capabilities

  • Validation metric: Distinct subcellular localization patterns consistent with RPS9 biology

• Immunoprecipitation:

  • Key consideration: Ability to bind native protein in solution

  • Validation metric: Enrichment of RPS9 and known interacting partners

• ELISA:

  • Key consideration: Quantitative detection range and standard curve linearity

  • Validation metric: Consistent detection across sample types with minimal matrix effects

Researchers should select antibodies specifically validated for their application of interest rather than assuming cross-application performance .

How should researchers approach experimental design when studying RPS9 in different cellular compartments?

For compartment-specific RPS9 studies:

• Nucleolar localization:

  • Use co-staining with nucleolar markers (nucleolin, fibrillarin)

  • Consider nucleolar isolation protocols followed by Western blotting

  • Implement super-resolution microscopy for precise localization

  • Use RPS9 antibody dilutions at the lower end of the recommended range for IF (around 1:100-1:200)

• Cytoplasmic ribosomes:

  • Combine with markers for mature ribosomes or translation factors

  • Consider subcellular fractionation to separate free vs. ribosome-bound RPS9

  • Use polysome profiling to distinguish different translational states

  • Optimal antibody dilutions typically fall in the middle of recommended ranges (1:300-1:500)

• Nuclear non-nucleolar localization:

  • Implement confocal microscopy with optical sectioning

  • Use nuclear extraction protocols to biochemically verify presence

  • Consider chromatin immunoprecipitation for DNA-associated functions

  • May require higher antibody concentrations due to potentially lower abundance

• Extra-ribosomal complexes:

  • Use size exclusion chromatography or gradient centrifugation to isolate complexes

  • Implement native gel electrophoresis followed by Western blotting

  • Combine with co-immunoprecipitation to identify novel interactions

  • May require optimization beyond standard dilution recommendations

Proper controls for each compartment and careful consideration of fixation methods are essential for accurate interpretation of RPS9 localization patterns.

How can researchers accurately interpret discrepancies in RPS9 detection between different antibodies?

When facing discrepancies between RPS9 antibodies:

When discrepancies persist, consider that they may reflect actual biological phenomena rather than technical artifacts, such as different pools or modified forms of RPS9 .

What statistical approaches are appropriate for quantifying RPS9 expression changes in disease models?

For robust statistical analysis of RPS9 expression:

• Normalization strategies:

  • For Western blots: Normalize to loading controls appropriate for the subcellular fraction (β-actin for total lysate; other ribosomal proteins for ribosomal fractions)

  • For IHC: Use tissue microarrays with internal controls and standardized scoring systems

  • For IF: Implement intensity normalization to nuclear staining or other house-keeping proteins

• Experimental design considerations:

  • Minimum of three biological replicates

  • Technical replicates within each biological sample

  • Appropriate controls (positive, negative, isotype)

  • Blinded analysis when possible

• Statistical tests based on data characteristics:

  • Parametric tests (t-test, ANOVA) if data follows normal distribution

  • Non-parametric alternatives (Mann-Whitney, Kruskal-Wallis) for non-normal data

  • Correlation analyses to relate RPS9 levels to clinical parameters

  • Survival analysis (Kaplan-Meier) when examining prognostic value

• Multiple testing correction:

  • Bonferroni for conservative approach

  • False Discovery Rate for balance between Type I and Type II errors

• Presentation standards:

  • Include both representative images and quantification

  • Report exact p-values rather than thresholds

  • Include measures of variance (standard deviation or standard error)

  • Explicitly state sample sizes for each experiment

These approaches help ensure that observed changes in RPS9 expression or localization reflect true biological differences rather than technical variability .

How can researchers distinguish between RPS9's canonical ribosomal functions and potential extra-ribosomal roles?

To differentiate between canonical and extra-ribosomal RPS9 functions:

• Subcellular localization analysis:

  • Use high-resolution imaging to identify RPS9 in unexpected cellular compartments

  • Perform biochemical fractionation to isolate non-ribosomal compartments

  • Compare RPS9 distribution with other ribosomal proteins to identify differential localization

• Protein interaction network mapping:

  • Perform RPS9 immunoprecipitation followed by mass spectrometry

  • Compare interactome with known ribosomal interactions

  • Validate novel interactions with reciprocal co-immunoprecipitation

• Functional separation strategies:

  • Design mutants that specifically disrupt ribosome incorporation but maintain protein stability

  • Use domain-specific antibodies that might differentially recognize ribosomal vs. non-ribosomal RPS9

  • Implement proximity labeling approaches to identify context-specific interactions

• Temporal analysis:

  • Study RPS9 during conditions when ribosome biogenesis is minimal

  • Examine rapid responses to stress before new ribosomes can be assembled

  • Track RPS9 in non-dividing cells with stable ribosome content

• Comparative ribosomal protein analysis:

  • Compare phenotypes of RPS9 depletion with other ribosomal proteins

  • Identify unique outcomes that aren't shared with other ribosomal protein deficiencies

  • Use rescue experiments to identify functional domains required for specific functions

These approaches can help identify activities of RPS9 that extend beyond its structural role in the ribosome, potentially revealing novel therapeutic targets .

What emerging technologies might enhance the utility of RPS9 antibodies in ribosome research?

Several cutting-edge technologies could expand RPS9 antibody applications:

• Super-resolution microscopy techniques:

  • STORM/PALM for nanometer-scale localization of RPS9 within ribosomes

  • Expansion microscopy to physically enlarge samples for improved visualization

  • Lattice light-sheet microscopy for live-cell imaging of RPS9 dynamics

• Proximity labeling methodologies:

  • BioID or TurboID fusions to map the RPS9 interactome in living cells

  • APEX2 for electron microscopy visualization of RPS9 at ultrastructural resolution

  • Split proximity labeling systems to identify condition-specific interactions

• Single-molecule approaches:

  • Single-molecule FISH combined with RPS9 immunostaining to correlate with specific mRNAs

  • Single-molecule tracking of labeled RPS9 to study ribosome dynamics

  • Optical tweezers or nanopore techniques incorporating RPS9 antibodies

• Spatially-resolved 'omics:

  • Spatial transcriptomics combined with RPS9 immunodetection

  • Mass spectrometry imaging to correlate RPS9 with the proteome across tissue sections

  • In situ sequencing to link RPS9-containing ribosomes with specific mRNAs

• CRISPR technologies:

  • CRISPR knock-in of split fluorescent proteins to visualize RPS9 incorporation into ribosomes

  • CRISPRi/a systems for controlled modulation of RPS9 expression

  • Base editing for introducing specific mutations in RPS9 without disrupting expression

These technologies could provide unprecedented insights into RPS9 function in ribosome assembly, translation regulation, and potential extra-ribosomal roles .

How might RPS9 antibodies contribute to translational research and therapeutic development?

RPS9 antibodies have significant potential in translational applications:

• Diagnostic development:

  • Tissue-based diagnostics using RPS9 antibodies to identify ribosomopathies

  • Liquid biopsy applications detecting modified RPS9 in circulation

  • Companion diagnostics for therapeutics targeting ribosome biogenesis

• Therapeutic target validation:

  • Evaluating RPS9 as a potential target in diseases with dysregulated translation

  • Screening compounds that modulate RPS9 incorporation into ribosomes

  • Monitoring treatment responses through changes in RPS9 expression or modification

• Drug development applications:

  • High-content screening using RPS9 antibodies to identify compounds affecting ribosome biogenesis

  • Target engagement studies to confirm drug interactions with ribosomal machinery

  • Toxicity assessments for compounds potentially disrupting translation

• Personalized medicine approaches:

  • Stratifying patients based on RPS9 expression or modification patterns

  • Predicting response to translation-targeting therapies

  • Monitoring treatment efficacy through RPS9-related biomarkers

• Advanced therapeutic modalities:

  • Developing RPS9 antibody-drug conjugates for targeted delivery to cells with aberrant ribosome biogenesis

  • Creating intrabodies targeting specific forms of RPS9

  • Designing aptamer-antibody chimeras for improved tissue penetration

These applications could bridge fundamental ribosome biology research with clinical applications, potentially leading to novel diagnostics and therapeutics for diseases involving ribosome dysfunction .